Mapping enterovirus A71 antigenic determinants from viral evolution

Sheng Wen Huang, Ching Hui Tai, Judith M. Fonville, Chin Hui Lin, Shih-Min Wang, Ching-Chuan Liu, Ih Jen Su, Derek J. Smith, Jen-Ren Wang

研究成果: Article

17 引文 (Scopus)

摘要

Human enterovirus A71 (EV-A71) belongs to the Enterovirus A species in the Picornaviridae family. Several vaccines against EV-A71, a disease causing severe neurological complications or even death, are currently under development and being tested in clinical trials, and preventative vaccination programs are expected to start soon. To characterize the potential for antigenic change of EV-A71, we compared the sequences of two antigenically diverse genotype B4 and B5 strains of EV-A71 and identified substitutions at residues 98, 145, and 164 in the VP1 capsid protein as antigenic determinants. To examine the effects of these three substitutions on antigenicity, we constructed a series of recombinant viruses containing different mutation combinations at these three residues with a reverse genetics system and then investigated the molecular basis of antigenic changes with antigenic cartography. We found that a novel EV-A71 mutant, containing lysine, glutamine, and glutamic acid at the respective residues 98, 145, and 164 in the VP1 capsid protein, exhibited neutralization reduction against patients' antisera and substantially increased virus binding ability to human cells. These observations indicated that this low-neutralization-reactive EV-A71 VP1-98K/145Q/164E mutant potentially increases viral binding ability and that surveillance studies should look out for these mutants, which could compromise vaccine efficacy.

原文English
頁(從 - 到)11500-11506
頁數7
期刊Journal of Virology
89
發行號22
DOIs
出版狀態Published - 2015 一月 1

指紋

Enterovirus
epitopes
Epitopes
binding capacity
coat proteins
neutralization
mutants
Enterovirus A
Human enterovirus
Capsid Proteins
Picornaviridae
vaccines
viruses
Vaccines
cartography
glutamic acid
glutamine
Virus Attachment
Reverse Genetics
antiserum

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

引用此文

Huang, Sheng Wen ; Tai, Ching Hui ; Fonville, Judith M. ; Lin, Chin Hui ; Wang, Shih-Min ; Liu, Ching-Chuan ; Su, Ih Jen ; Smith, Derek J. ; Wang, Jen-Ren. / Mapping enterovirus A71 antigenic determinants from viral evolution. 於: Journal of Virology. 2015 ; 卷 89, 編號 22. 頁 11500-11506.
@article{9eb94b3b599e4f61917bd4221db0f4ff,
title = "Mapping enterovirus A71 antigenic determinants from viral evolution",
abstract = "Human enterovirus A71 (EV-A71) belongs to the Enterovirus A species in the Picornaviridae family. Several vaccines against EV-A71, a disease causing severe neurological complications or even death, are currently under development and being tested in clinical trials, and preventative vaccination programs are expected to start soon. To characterize the potential for antigenic change of EV-A71, we compared the sequences of two antigenically diverse genotype B4 and B5 strains of EV-A71 and identified substitutions at residues 98, 145, and 164 in the VP1 capsid protein as antigenic determinants. To examine the effects of these three substitutions on antigenicity, we constructed a series of recombinant viruses containing different mutation combinations at these three residues with a reverse genetics system and then investigated the molecular basis of antigenic changes with antigenic cartography. We found that a novel EV-A71 mutant, containing lysine, glutamine, and glutamic acid at the respective residues 98, 145, and 164 in the VP1 capsid protein, exhibited neutralization reduction against patients' antisera and substantially increased virus binding ability to human cells. These observations indicated that this low-neutralization-reactive EV-A71 VP1-98K/145Q/164E mutant potentially increases viral binding ability and that surveillance studies should look out for these mutants, which could compromise vaccine efficacy.",
author = "Huang, {Sheng Wen} and Tai, {Ching Hui} and Fonville, {Judith M.} and Lin, {Chin Hui} and Shih-Min Wang and Ching-Chuan Liu and Su, {Ih Jen} and Smith, {Derek J.} and Jen-Ren Wang",
year = "2015",
month = "1",
day = "1",
doi = "10.1128/JVI.02035-15",
language = "English",
volume = "89",
pages = "11500--11506",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "22",

}

Huang, SW, Tai, CH, Fonville, JM, Lin, CH, Wang, S-M, Liu, C-C, Su, IJ, Smith, DJ & Wang, J-R 2015, 'Mapping enterovirus A71 antigenic determinants from viral evolution', Journal of Virology, 卷 89, 編號 22, 頁 11500-11506. https://doi.org/10.1128/JVI.02035-15

Mapping enterovirus A71 antigenic determinants from viral evolution. / Huang, Sheng Wen; Tai, Ching Hui; Fonville, Judith M.; Lin, Chin Hui; Wang, Shih-Min; Liu, Ching-Chuan; Su, Ih Jen; Smith, Derek J.; Wang, Jen-Ren.

於: Journal of Virology, 卷 89, 編號 22, 01.01.2015, p. 11500-11506.

研究成果: Article

TY - JOUR

T1 - Mapping enterovirus A71 antigenic determinants from viral evolution

AU - Huang, Sheng Wen

AU - Tai, Ching Hui

AU - Fonville, Judith M.

AU - Lin, Chin Hui

AU - Wang, Shih-Min

AU - Liu, Ching-Chuan

AU - Su, Ih Jen

AU - Smith, Derek J.

AU - Wang, Jen-Ren

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Human enterovirus A71 (EV-A71) belongs to the Enterovirus A species in the Picornaviridae family. Several vaccines against EV-A71, a disease causing severe neurological complications or even death, are currently under development and being tested in clinical trials, and preventative vaccination programs are expected to start soon. To characterize the potential for antigenic change of EV-A71, we compared the sequences of two antigenically diverse genotype B4 and B5 strains of EV-A71 and identified substitutions at residues 98, 145, and 164 in the VP1 capsid protein as antigenic determinants. To examine the effects of these three substitutions on antigenicity, we constructed a series of recombinant viruses containing different mutation combinations at these three residues with a reverse genetics system and then investigated the molecular basis of antigenic changes with antigenic cartography. We found that a novel EV-A71 mutant, containing lysine, glutamine, and glutamic acid at the respective residues 98, 145, and 164 in the VP1 capsid protein, exhibited neutralization reduction against patients' antisera and substantially increased virus binding ability to human cells. These observations indicated that this low-neutralization-reactive EV-A71 VP1-98K/145Q/164E mutant potentially increases viral binding ability and that surveillance studies should look out for these mutants, which could compromise vaccine efficacy.

AB - Human enterovirus A71 (EV-A71) belongs to the Enterovirus A species in the Picornaviridae family. Several vaccines against EV-A71, a disease causing severe neurological complications or even death, are currently under development and being tested in clinical trials, and preventative vaccination programs are expected to start soon. To characterize the potential for antigenic change of EV-A71, we compared the sequences of two antigenically diverse genotype B4 and B5 strains of EV-A71 and identified substitutions at residues 98, 145, and 164 in the VP1 capsid protein as antigenic determinants. To examine the effects of these three substitutions on antigenicity, we constructed a series of recombinant viruses containing different mutation combinations at these three residues with a reverse genetics system and then investigated the molecular basis of antigenic changes with antigenic cartography. We found that a novel EV-A71 mutant, containing lysine, glutamine, and glutamic acid at the respective residues 98, 145, and 164 in the VP1 capsid protein, exhibited neutralization reduction against patients' antisera and substantially increased virus binding ability to human cells. These observations indicated that this low-neutralization-reactive EV-A71 VP1-98K/145Q/164E mutant potentially increases viral binding ability and that surveillance studies should look out for these mutants, which could compromise vaccine efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84945952706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945952706&partnerID=8YFLogxK

U2 - 10.1128/JVI.02035-15

DO - 10.1128/JVI.02035-15

M3 - Article

C2 - 26339057

AN - SCOPUS:84945952706

VL - 89

SP - 11500

EP - 11506

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 22

ER -